Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Accumulated Expenses (2021 - 2025)

Historic Accumulated Expenses for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $11.0 million.

  • Prime Medicine's Accumulated Expenses fell 4112.61% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 4112.61%. This contributed to the annual value of $15.9 million for FY2024, which is 1271.44% up from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Accumulated Expenses is $11.0 million, which was down 4112.61% from $12.2 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Accumulated Expenses ranged from a high of $37.2 million in Q4 2021 and a low of $6.5 million during Q3 2022
  • In the last 5 years, Prime Medicine's Accumulated Expenses had a median value of $10.9 million in 2024 and averaged $13.2 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 7126.26% in 2022, then skyrocketed by 11474.73% in 2023.
  • Quarter analysis of 5 years shows Prime Medicine's Accumulated Expenses stood at $37.2 million in 2021, then crashed by 71.26% to $10.7 million in 2022, then surged by 32.02% to $14.1 million in 2023, then increased by 12.71% to $15.9 million in 2024, then crashed by 30.84% to $11.0 million in 2025.
  • Its Accumulated Expenses stands at $11.0 million for Q3 2025, versus $12.2 million for Q2 2025 and $9.2 million for Q1 2025.